Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome800
Zolbetuximab treatment in metastatic gastric cancer547
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity532
Hybrid EASL Congress 2023520
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology474
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection454
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis419
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa394
Mapping neuroimmune interactions in the gut373
Digestive Disease Week 2022356
Nomenclature of HBV core protein-targeting antivirals340
Black–White disparities across the colorectal cancer care continuum in the USA319
Western lifestyle, metaflammation and the cell of origin of colon cancer255
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection249
2023 FDA approvals in gastroenterology and hepatology246
Large language models for clinical decision support in gastroenterology and hepatology242
Advancing nutrition science for global health230
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed228
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis206
Artificial intelligence and automation in endoscopy and surgery205
Oral microbiome therapy efficacious for recurrent C. difficile infection202
Wound healing in the colon195
Hepatic IRF3 in glucose intolerance193
New understanding of hepatobiliary MRI185
Decoding therapy resistance in liver tumours: a giant leap183
GWAS reveals variants for alcohol-related hepatocellular carcinoma183
Metastatic pancreatic cancer and the liver183
Lessons from incretin-based therapy in MASH and obesity173
A crucial Fusobacterium nucleatum clade in colorectal cancer170
Food as medicine in gastrointestinal cancer therapy166
Inflammatory bowel disease in pregnancy and breastfeeding161
The global burden of coeliac disease: opportunities and challenges157
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges156
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation142
Bacteriophages and their potential for treatment of gastrointestinal diseases141
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract137
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases136
Hepatocyte-derived biomarkers in alcohol-related cirrhosis135
Integrated systems approach to identify environmental factors in intestinal inflammation128
HDCA ameliorates NAFLD in mice128
Preventing the progression of cirrhosis to decompensation and death127
Metabolic diseases in the East Asian populations127
Characterizing the genomic landscape of colorectal cancer124
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease124
Implications of the evolving knowledge of the genetic architecture of MASLD124
Lanifibranor and NASH resolution123
Estimating dietary intake from human stool DNA119
The path to successful hepatitis C elimination in Spain118
Probiotics for preterms: sharing complex decision-making117
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment109
Proteases in intestinal health and disease105
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management105
SSRIs and depression: role of gut–brain communication104
Medical therapy of paediatric inflammatory bowel disease103
Liver, ageing and disease101
Current and future colorectal cancer screening strategies100
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook99
Human intestinal B cells in inflammatory diseases99
NAFLD prevalence in older patients with T2DM97
Phase III results for first-line treatment for metastatic colorectal cancer96
Author Correction: Hepatic immune regulation and sex disparities92
ECCO’2491
The future of pathology in gastroenterology and hepatology89
Microbiota and colorectal cancer — controlling for confounders challenges associations88
GLP1R agonists in NAFLD: a promising therapy on the horizon86
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’83
Enteric nervous system transfers stress to the gut81
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance80
Gut microbiome and autism spectrum disorder79
Transforming the landscape of liver cancer detection and care79
Hepatic glucose metabolism in the steatotic liver78
Neutrophils as potential therapeutic targets in hepatocellular carcinoma75
Artificial intelligence in liver cancer — new tools for research and patient management75
0.38639187812805